Over the past three months, CareDx's consensus EPS estimate for the current year has increased 113.6%. The stock currently has a Zacks Rank #1 (Strong Buy). MacroGenics is a member of our Medical group, which includes 913 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst. The Zacks Rank is a proven model ...